{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:30:09Z","timestamp":1777501809551,"version":"3.51.4"},"reference-count":31,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To describe the epidemiological, clinical and laboratory characteristics and clinical progress of patients hospitalized with heart failure (HF) who started treatment with empagliflozin before discharge.\n            <jats:bold>Methods:<\/jats:bold>\n            We performed a retrospective observational study of patients aged \u226518\u00a0years admitted to the Internal Medicine Department of University Hospital Jaen, Jaen, Spain with acute HF between 1 May 2022 and 31 May 2023. Patients had to have a life expectancy of \u22651\u00a0year and have started treatment with empagliflozin during admission.\n            <jats:bold>Results:<\/jats:bold>\n            We included 112 patients (mean age, 85.2\u00a0\u00b1\u00a06.5\u00a0years; 67.9% women; 35.7 and 31.3% in NYHA functional classes III and IV; 73.2% with HF and preserved ejection fraction). Before admission, 80.4% were taking loop diuretics, 70.6% renin\u2013angiotensin\u2013aldosterone system inhibitors, 49.1% betablockers and 25% mineralocorticoid receptor antagonists. At admission, 94.6% were taking furosemide (15.2% at high doses, 36.6% at intermediate doses). The dose of furosemide was reduced at initiation of empagliflozin. At the end of follow-up, 13.4% of patients had died, 93.8% of the survivors continued treatment with empagliflozin and 26.8% had attended the emergency department with signs and symptoms of HF.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Introduction of empagliflozin before discharge from hospital in patients admitted with HF made it possible to reduce the dose of diuretics during admission. The frequency of complications was as expected, and treatment was largely maintained.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0027","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T13:10:54Z","timestamp":1716556254000},"source":"Crossref","is-referenced-by-count":1,"title":["Progress of patients hospitalized with acute heart failure treated with empagliflozin"],"prefix":"10.57264","volume":"13","author":[{"given":"Manuel","family":"Raya-Cruz","sequence":"first","affiliation":[{"name":"Servicio Medicina Interna, Hospital Universitario de Ja\u00e9n, 23007 Ja\u00e9n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier Gasc\u00f3n","family":"Jurado","sequence":"additional","affiliation":[{"name":"Servicio Medicina Interna, Hospital Universitario de Ja\u00e9n, 23007 Ja\u00e9n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo Olalla","family":"de la Torre Peregr\u00edn","sequence":"additional","affiliation":[{"name":"Servicio Medicina Interna, Hospital Universitario de Ja\u00e9n, 23007 Ja\u00e9n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s","family":"Mont\u00fafar","sequence":"additional","affiliation":[{"name":"Servicio Medicina Interna, Hospital Universitario de Ja\u00e9n, 23007 Ja\u00e9n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agust\u00edn Rodr\u00edguez","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Servicio Medicina Interna, Hospital Universitario de Ja\u00e9n, 23007 Ja\u00e9n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco G\u00f3mez","family":"Delgado","sequence":"additional","affiliation":[{"name":"Servicio Medicina Interna, Hospital Universitario de Ja\u00e9n, 23007 Ja\u00e9n, Spain"},{"name":"CIBER Fisiopatologia Obesidad y Nutricion (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"7","key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.3390\/jcm11175199","article-title":"Prevalence, characteristics, management and outcomes of patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain","volume":"11","author":"Escobar C","year":"2022","unstructured":"Escobar C, Palacios B, Varela L Prevalence, characteristics, management and outcomes of patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain. J. Clin. Med. 11(7), 5199 (2022).","journal-title":"J. Clin. Med."},{"key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21037\/amj.2020.03.03","article-title":"Global epidemiology and future trends of heart failure","volume":"5","author":"Lippi G","year":"2020","unstructured":"Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med. J. 5, 15 (2020).","journal-title":"AME Med. J."},{"issue":"6","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber Y","year":"2015","unstructured":"Gerber Y, Weston SA, Redfield MM A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern. Med. 175(6), 996\u20131004 (2015).","journal-title":"JAMA Intern. Med."},{"issue":"4","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/ehf2.13921","article-title":"Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort","volume":"9","author":"Chen S","year":"2022","unstructured":"Chen S, Huang Z, Liang Y Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort. ESC Heart. Fail. 9(4), 2336\u20132347 (2022).","journal-title":"ESC Heart. Fail."},{"issue":"10","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure. a contemporary perspective","volume":"128","author":"Roger VL","year":"2021","unstructured":"Roger VL. Epidemiology of heart failure. a contemporary perspective. Circ. Res. 128(10), 1421\u20131434 (2021).","journal-title":"Circ. Res."},{"issue":"8","key":"e_1_3_7_8_2","first-page":"499","article-title":"Executive summary of the 2023 update on the consensus regarding basic conduct during hospital admission for patients with acute heart failure","volume":"223","author":"Fern\u00e1ndez-Rodr\u00edguez JM","year":"2023","unstructured":"Fern\u00e1ndez-Rodr\u00edguez JM, Casado J, Formiga F Executive summary of the 2023 update on the consensus regarding basic conduct during hospital admission for patients with acute heart failure. Rev. Clin. Esp. (Barc) 223(8), 499\u2013509 (2023).","journal-title":"Rev. Clin. Esp. (Barc)"},{"issue":"36","key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh T","year":"2021","unstructured":"McDonagh T, Metra M, Adamo M 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 42(36), 3599\u20133726 (2021).","journal-title":"Eur Heart J."},{"issue":"16","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385(16), 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387(12), 1089\u20131098 (2022).","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC Expert Consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson MM","year":"2023","unstructured":"Kittleson MM, Panjrath GS, Amancherla K 2023 ACC Expert Consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J. Am. Coll. Cardiol. 81(18), 1835\u20131878 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"37","key":"e_1_3_7_13_2","first-page":"3627","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh T","year":"2023","unstructured":"McDonagh T, Metra M, Adamo M 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 44(37), 3627\u20133639 (2023).","journal-title":"Eur. Heart J."},{"issue":"3","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors AA","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat. Med. 28(3), 568\u2013574 (2022).","journal-title":"Nat. Med."},{"issue":"4","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman K","year":"2020","unstructured":"Damman K, Beusekamp JC, Boorsma EM Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur. J. Heart Fail. 22(4), 713\u2013722 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejim.2022.06.008","article-title":"Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular events in acute heart failure. A real-world analysis","volume":"104","author":"L\u00f3pez-Vilella R","year":"2022","unstructured":"L\u00f3pez-Vilella R, Trenado VD, Cervera BG Sodium-glucose cotransporter 2 inhibitors reduce cardiovascular events in acute heart failure. A real-world analysis. Eur. J. Intern. Med. 104, 128\u2013130 (2022).","journal-title":"Eur. J. Intern. Med."},{"issue":"3","key":"e_1_3_7_17_2","first-page":"130","article-title":"SEA 2022 Standards for Global Control of Cardiovascular Risk","volume":"34","author":"Mostaza JM","year":"2022","unstructured":"Mostaza JM, Pint\u00f3 X, Armario P SEA 2022 Standards for Global Control of Cardiovascular Risk. Clin. Investig. Arterioscler. 34(3), 130\u2013179 (2022).","journal-title":"Clin. Investig. Arterioscler."},{"issue":"25","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1016\/j.jacc.2021.04.070","article-title":"Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week","volume":"77","author":"Lam CSP","year":"2021","unstructured":"Lam CSP, Solomon SD. Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 77(25), 3217\u20133225 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"e_1_3_7_19_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2217\/fca-2023-0014","article-title":"Benefits of dapagliflozin in the whole spectrum of heart failure in clinical practice: the RICA registry","volume":"19","author":"Montero-P\u00e9rez-Barquero M","year":"2023","unstructured":"Montero-P\u00e9rez-Barquero M, Escobar-Cervantes C, D\u00e1vila-Ramos MF Benefits of dapagliflozin in the whole spectrum of heart failure in clinical practice: the RICA registry. Future Cardiol. 19(6), 323\u2013332 (2023).","journal-title":"Future Cardiol."},{"key":"e_1_3_7_20_2","doi-asserted-by":"crossref","first-page":"1894155","DOI":"10.1155\/2021\/1894155","article-title":"Eligibility of dapagliflozin and empagliflozin in a real-world heart failure population","volume":"2021","author":"H\u00e5kansson E","year":"2021","unstructured":"H\u00e5kansson E, Norberg H, Sj\u00e4lander S Eligibility of dapagliflozin and empagliflozin in a real-world heart failure population. Cardiovasc. Ther. 2021, 1894155 (2021).","journal-title":"Cardiovasc. Ther."},{"issue":"7","key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cardfail.2022.04.011","article-title":"Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population","volume":"28","author":"Thorvaldsen T","year":"2022","unstructured":"Thorvaldsen T, Ferrannini G, Mellbin L Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population. J. Card. Fail. 28(7), 1050\u20131062 (2022).","journal-title":"J. Card. Fail."},{"issue":"13","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"e029071","DOI":"10.1161\/JAHA.122.029071","article-title":"Eligibility for the 4 pharmacological pillars in heart failure with reduced ejection fraction at discharge","volume":"12","author":"D'Amario D","year":"2023","unstructured":"D'Amario D, Rodolico D, Delvinioti A Eligibility for the 4 pharmacological pillars in heart failure with reduced ejection fraction at discharge. J. Am. Heart Assoc. 12(13), e029071 (2023).","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"e_1_3_7_23_2","first-page":"347","article-title":"Prognostic impact of physician specialty on the prognosis of outpatients with heart failure: propensity matched analysis of the REDINSCOR and RICA registries","volume":"70","author":"\u00c1lvarez-Garc\u00eda J","year":"2017","unstructured":"\u00c1lvarez-Garc\u00eda J, Salamanca-Bautista P, Ferrero-Gregori A Prognostic impact of physician specialty on the prognosis of outpatients with heart failure: propensity matched analysis of the REDINSCOR and RICA registries. Rev. Esp. Cardiol. (Engl Ed.) 70(5), 347\u2013354 (2017).","journal-title":"Rev. Esp. Cardiol. (Engl Ed.)"},{"issue":"1","key":"e_1_3_7_24_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/jcm12010099","article-title":"The prescription pattern of heart failure medications in reduced, mildly reduced, and preserved ejection fractions","volume":"12","author":"Rastogi T","year":"2022","unstructured":"Rastogi T, Duarte K, Huttin O The prescription pattern of heart failure medications in reduced, mildly reduced, and preserved ejection fractions. J. Clin. Med. 12(1), 99 (2022).","journal-title":"J. Clin. Med."},{"issue":"8","key":"e_1_3_7_25_2","first-page":"464","article-title":"Initiation, maintenance and withdrawal of disease-modifying treatment during an acute heart failure decompensation","volume":"219","author":"Trull\u00e0s JC","year":"2019","unstructured":"Trull\u00e0s JC, Formiga F, Casado J Initiation, maintenance and withdrawal of disease-modifying treatment during an acute heart failure decompensation. Rev. Clin. Esp. (Barc) 219(8), 464\u2013466 (2019).","journal-title":"Rev. Clin. Esp. (Barc)"},{"key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.15420\/ecr.2022.62","article-title":"When should we start sodium-glucose co-transporter inhibitors in patients with heart failure? The importance of early intervention","volume":"18","author":"Iguchi M","year":"2023","unstructured":"Iguchi M, Wada H, Mart\u00ednez F When should we start sodium-glucose co-transporter inhibitors in patients with heart failure? The importance of early intervention. Eur. Cardiol. 18, e41 (2023).","journal-title":"Eur. Cardiol."},{"issue":"1","key":"e_1_3_7_27_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ejhf.2382","article-title":"In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable","volume":"24","author":"Greene SJ","year":"2022","unstructured":"Greene SJ, Butler J, Fonarow GC. In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. Eur. J. Heart Fail. 24(1), 227\u2013229 (2022).","journal-title":"Eur. J. Heart Fail."},{"issue":"10","key":"e_1_3_7_28_2","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/ejhf.2982","article-title":"Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: findings from EMPULSE","volume":"25","author":"Ferreira JP","year":"2023","unstructured":"Ferreira JP, Blatchford JP, Teerlink JR Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: findings from EMPULSE. Eur. J. Heart Fail. 25(10), 1797\u20131805 (2023).","journal-title":"Eur. J. Heart Fail."},{"issue":"24","key":"e_1_3_7_29_2","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/ajhp\/zxad177","article-title":"Utilization rates and predictors of sodium glucose cotransporter 2 inhibitor use in patients with heart failure with or without Type 2 diabetes","volume":"80","author":"Ray GM","year":"2023","unstructured":"Ray GM, Bermudez SR, Anderson JR Utilization rates and predictors of sodium glucose cotransporter 2 inhibitor use in patients with heart failure with or without Type 2 diabetes. Am. J. Health Syst. Pharm. 80(24), 1787\u20131795 (2023).","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"6","key":"e_1_3_7_30_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jchf.2023.01.018","article-title":"Recency of heart failure hospitalization, outcomes, and the effect of empagliflozin: an EMPEROR-Pooled Analysis","volume":"11","author":"Ferreira JP","year":"2023","unstructured":"Ferreira JP, Zannad F, Butler J Recency of heart failure hospitalization, outcomes, and the effect of empagliflozin: an EMPEROR-Pooled Analysis. JACC Heart Fail. 11(6), 702\u2013712 (2023).","journal-title":"JACC Heart Fail."},{"issue":"15","key":"e_1_3_7_31_2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer M","year":"2020","unstructured":"Packer M, Anker SD, Butler J Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383(15), 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_3_7_32_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2018.06.011","article-title":"Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization","volume":"7","author":"Bhagat AA","year":"2019","unstructured":"Bhagat AA, Greene SJ, Vaduganathan M Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. JACC Heart Fail. 7(1), 1\u201312 (2019).","journal-title":"JACC Heart Fail."},{"issue":"7","key":"e_1_3_7_33_2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/ejhf.2928","article-title":"Association between a hospitalization for heart failure and the initiation\/discontinuation of guideline-recommended treatments: an analysis from the Swedish Heart Failure Registry","volume":"25","author":"Schrage B","year":"2023","unstructured":"Schrage B, Lund LH, Benson L Association between a hospitalization for heart failure and the initiation\/discontinuation of guideline-recommended treatments: an analysis from the Swedish Heart Failure Registry. Eur. J. Heart Fail. 25(7), 1132\u20131144 (2023).","journal-title":"Eur. J. Heart Fail."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T10:34:35Z","timestamp":1716978875000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.57264\/cer-2024-0027"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0027","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"article-number":"e240027"}}